Citadel Advisors
TTHI

Citadel Advisors’s TRANSITION THERAPEUTICS INC (CANADA) TTHI Stock Holding History

Citadel Advisors’s Portfolio TTHI Stock Details TTHI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-27,756
Closed -$36K – 8023
2016
Q1 		$36K Buy
+27,756
New +$32.1K ﹤0.01% 6340
2015
Q3 		– Sell
-11,255
Closed -$24K – 9744
2015
Q2 		$24K Buy
+11,255
New +$78.9K ﹤0.01% 8077

Other funds holding TTHI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
NC
NBW Capital Boston, Massachusetts $464M AUM 21.25% 1-Year Est. Return
KAM
Kassirer Asset Management Toronto, Ontario, Canada $4.07M AUM 49.71% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Citadel Advisors's TTHI Position: Q2 2016 in Review

Citadel Advisors sold out of TRANSITION THERAPEUTICS INC (CANADA) (TTHI) in Q2 2016, closing a stake of 27,756 shares — an estimated $36K sold.

Citadel Advisors first reported a position in TTHI in Q2 2015 and held it in 2 quarters. The position peaked at $36K in Q1 2016. 20 funds tracked by Wall St. Rank hold TTHI as of Q2 2016.

  • Citadel Advisors reported no remaining TRANSITION THERAPEUTICS INC (CANADA) position as of Q2 2016 after selling out during the quarter.
  • Citadel Advisors sold 27,756 TRANSITION THERAPEUTICS INC (CANADA) shares in Q2 2016, an estimated $36K.
  • Citadel Advisors first reported a position in TRANSITION THERAPEUTICS INC (CANADA) in Q2 2015 and held it in 2 quarters.
  • Citadel Advisors's TRANSITION THERAPEUTICS INC (CANADA) position peaked at $36K in Q1 2016.
  • 20 funds tracked by Wall St. Rank held TRANSITION THERAPEUTICS INC (CANADA) as of Q2 2016.

Based on Citadel Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.